Target Price | $6.20 |
Price | $1.61 |
Potential |
285.09%
register free of charge
|
Number of Estimates | 5 |
5 Analysts have issued a price target Lexicon Pharmaceuticals, Inc. 2025 .
The average Lexicon Pharmaceuticals, Inc. target price is $6.20.
This is
285.09%
register free of charge
$10.00
521.12%
register free of charge
$2.00
24.22%
register free of charge
|
|
A rating was issued by 6 analysts: 4 Analysts recommend Lexicon Pharmaceuticals, Inc. to buy, 2 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Lexicon Pharmaceuticals, Inc. stock has an average upside potential 2025 of
285.09%
register free of charge
|
Dec '23 |
2024 Estimates |
|
---|---|---|
Revenue Million $ | 1.20 | 16.40 |
757.14% | 1,266.29% | |
EBITDA Margin | -14,266.67% | -1,304.00% |
80.09% | 90.86% | |
Net Margin | -24,099.33% | -1,489.77% |
84.95% | 93.82% |
6 Analysts have issued a sales forecast Lexicon Pharmaceuticals, Inc. 2024 . The average Lexicon Pharmaceuticals, Inc. sales estimate is
This results in the following potential growth metrics:
2 Analysts have issued an Lexicon Pharmaceuticals, Inc. EBITDA forecast 2024. The average Lexicon Pharmaceuticals, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
6 Lexicon Pharmaceuticals, Inc. Analysts have issued a net profit forecast 2024. The average Lexicon Pharmaceuticals, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '23 |
2024 Estimates |
|
---|---|---|
Earnings Per Share $ | -0.80 | -0.68 |
29.03% | 15.00% | |
P/E | negative | |
EV/Sales | 23.04 |
6 Analysts have issued a Lexicon Pharmaceuticals, Inc. forecast for earnings per share. The average Lexicon Pharmaceuticals, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the Lexicon Pharmaceuticals, Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Lexicon Pharmaceuticals, Inc....
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.